FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression

In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting therapy zuranolone Friday as the first pill for postpartum depression—but rejected the treatment for major depressive disorder.